West Cancer Center, Germantown, TN
Lee S. Schwartzberg, Matti S. Aapro
| Complete Response | No Significant Nausea | ||
% patients | IV NEPA (N = 200) | Oral NEPA (N = 202) | IV NEPA (N = 200) | Oral NEPA (N = 202) |
Day 1 | 86.5 | 88.6 | 84.0 | 85.1 |
Day 2 | 84.0 | 85.6 | 85.0 | 85.1 |
Day 3 | 81.5 | 84.7 | 80.0 | 82.7 |
Day 4 | 88.0 | 90.1 | 85.5 | 86.1 |
Day 5 | 92.0 | 91.6 | 88.5 | 88.1 |
Days 1-5 | 73.0 | 77.2 | 70.0 | 74.8 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2022 ASCO Annual Meeting
First Author: Camilla Vieira de Reboucas
2024 ASCO Annual Meeting
First Author: Tilak Tvsvgk
2019 ASCO Annual Meeting
First Author: Lee S. Schwartzberg
2023 ASCO Annual Meeting
First Author: Venkatraman Radhakrishnan